LSTA
Lisata Therapeutics, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
2.92
P/S
265.66
EV/EBITDA
-1.65
DCF Value
$1.90
FCF Yield
-35.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
91.2%
Operating Margin
-10711.2%
Net Margin
-9756.5%
ROE
-84.4%
ROA
-93.5%
ROIC
-117.3%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $100.0K | $-3.0M | $-0.33 |
| FY 2025 | $170.0K | $-16.6M | $-1.91 |
| Q3 2025 | $0.00 | $-4.2M | $-0.49 |
| Q2 2025 | $70.0K | $-4.7M | $-0.54 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.11
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.